Attovia Therapeutics makes a strong start to public trading after pricing and completing an upsized initial public offering (IPO). According to reports, the company prices its offering at $17 per share, and the IPO is upsized to a targeted total raise of about $289 million. The trading debut then follows with shares rising sharply, with one outlet reporting a roughly 24% increase at the start of trading. Across the coverage provided, the key sequence is that Attovia first completes the IPO pricing process and then begins trading shortly afterward, with the stock’s debut reflecting investor demand. The sources agree on the main deal terms discussed publicly—share price at $17 and an upsized size intended to raise approximately $289 million—and on the outcome of the debut, namely a substantial share price gain shortly after listings. The reporting does not provide additional details about use of proceeds, underwriters, or lock-up terms in the information supplied.